Cargando…

Determinants of exercise intolerance in breast cancer patients prior to anthracycline chemotherapy

Women with early‐stage breast cancer have reduced peak exercise oxygen uptake (peak VO(2)). The purpose of this study was to evaluate peak VO(2) and right (RV) and left (LV) ventricular function prior to adjuvant chemotherapy. Twenty‐nine early‐stage breast cancer patients (mean age: 48 years) and 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Beaudry, Rhys I., Howden, Erin J., Foulkes, Steve, Bigaran, Ashley, Claus, Piet, Haykowsky, Mark J., Gerche, Andre La
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328913/
https://www.ncbi.nlm.nih.gov/pubmed/30632311
http://dx.doi.org/10.14814/phy2.13971
_version_ 1783386731132747776
author Beaudry, Rhys I.
Howden, Erin J.
Foulkes, Steve
Bigaran, Ashley
Claus, Piet
Haykowsky, Mark J.
Gerche, Andre La
author_facet Beaudry, Rhys I.
Howden, Erin J.
Foulkes, Steve
Bigaran, Ashley
Claus, Piet
Haykowsky, Mark J.
Gerche, Andre La
author_sort Beaudry, Rhys I.
collection PubMed
description Women with early‐stage breast cancer have reduced peak exercise oxygen uptake (peak VO(2)). The purpose of this study was to evaluate peak VO(2) and right (RV) and left (LV) ventricular function prior to adjuvant chemotherapy. Twenty‐nine early‐stage breast cancer patients (mean age: 48 years) and 10 age‐matched healthy women were studied. Participants performed an upright cycle exercise test with expired gas analysis to measure peak VO(2). RV and LV volumes and function were measured at rest, submaximal and peak supine cycle exercise using cardiac magnetic resonance imaging. Peak VO(2) was significantly lower in breast cancer patients versus controls (1.7 ± 0.4 vs. 2.3 ± 0.5 L/min, P = 0.0013; 25 ± 6 vs. 35 ± 6 mL/kg/min, P = 0.00009). No significant difference was found between groups for peak upright exercise heart rate (174 ± 13 vs. 169 ± 16 bpm, P = 0.39). Rest, submaximal and peak exercise RV and LV end‐diastolic and end‐systolic volume index, stroke index, and cardiac index were significantly lower in breast cancer patients versus controls (P < 0.05 for all). No significant difference was found between groups for rest and exercise RV and LV ejection fraction. Despite preserved RV and LV ejection fraction, the decreased peak VO(2) in early‐stage breast cancer patients prior to adjuvant chemotherapy is due in part to decreased peak cardiac index secondary to reductions in RV and LV end‐diastolic volumes.
format Online
Article
Text
id pubmed-6328913
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-63289132019-01-16 Determinants of exercise intolerance in breast cancer patients prior to anthracycline chemotherapy Beaudry, Rhys I. Howden, Erin J. Foulkes, Steve Bigaran, Ashley Claus, Piet Haykowsky, Mark J. Gerche, Andre La Physiol Rep Original Research Women with early‐stage breast cancer have reduced peak exercise oxygen uptake (peak VO(2)). The purpose of this study was to evaluate peak VO(2) and right (RV) and left (LV) ventricular function prior to adjuvant chemotherapy. Twenty‐nine early‐stage breast cancer patients (mean age: 48 years) and 10 age‐matched healthy women were studied. Participants performed an upright cycle exercise test with expired gas analysis to measure peak VO(2). RV and LV volumes and function were measured at rest, submaximal and peak supine cycle exercise using cardiac magnetic resonance imaging. Peak VO(2) was significantly lower in breast cancer patients versus controls (1.7 ± 0.4 vs. 2.3 ± 0.5 L/min, P = 0.0013; 25 ± 6 vs. 35 ± 6 mL/kg/min, P = 0.00009). No significant difference was found between groups for peak upright exercise heart rate (174 ± 13 vs. 169 ± 16 bpm, P = 0.39). Rest, submaximal and peak exercise RV and LV end‐diastolic and end‐systolic volume index, stroke index, and cardiac index were significantly lower in breast cancer patients versus controls (P < 0.05 for all). No significant difference was found between groups for rest and exercise RV and LV ejection fraction. Despite preserved RV and LV ejection fraction, the decreased peak VO(2) in early‐stage breast cancer patients prior to adjuvant chemotherapy is due in part to decreased peak cardiac index secondary to reductions in RV and LV end‐diastolic volumes. John Wiley and Sons Inc. 2019-01-10 /pmc/articles/PMC6328913/ /pubmed/30632311 http://dx.doi.org/10.14814/phy2.13971 Text en © 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of The Physiological Society and the American Physiological Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Beaudry, Rhys I.
Howden, Erin J.
Foulkes, Steve
Bigaran, Ashley
Claus, Piet
Haykowsky, Mark J.
Gerche, Andre La
Determinants of exercise intolerance in breast cancer patients prior to anthracycline chemotherapy
title Determinants of exercise intolerance in breast cancer patients prior to anthracycline chemotherapy
title_full Determinants of exercise intolerance in breast cancer patients prior to anthracycline chemotherapy
title_fullStr Determinants of exercise intolerance in breast cancer patients prior to anthracycline chemotherapy
title_full_unstemmed Determinants of exercise intolerance in breast cancer patients prior to anthracycline chemotherapy
title_short Determinants of exercise intolerance in breast cancer patients prior to anthracycline chemotherapy
title_sort determinants of exercise intolerance in breast cancer patients prior to anthracycline chemotherapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328913/
https://www.ncbi.nlm.nih.gov/pubmed/30632311
http://dx.doi.org/10.14814/phy2.13971
work_keys_str_mv AT beaudryrhysi determinantsofexerciseintoleranceinbreastcancerpatientspriortoanthracyclinechemotherapy
AT howdenerinj determinantsofexerciseintoleranceinbreastcancerpatientspriortoanthracyclinechemotherapy
AT foulkessteve determinantsofexerciseintoleranceinbreastcancerpatientspriortoanthracyclinechemotherapy
AT bigaranashley determinantsofexerciseintoleranceinbreastcancerpatientspriortoanthracyclinechemotherapy
AT clauspiet determinantsofexerciseintoleranceinbreastcancerpatientspriortoanthracyclinechemotherapy
AT haykowskymarkj determinantsofexerciseintoleranceinbreastcancerpatientspriortoanthracyclinechemotherapy
AT gercheandrela determinantsofexerciseintoleranceinbreastcancerpatientspriortoanthracyclinechemotherapy